Cutting edge: The IκB Kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis

Journal of Immunology

Volumn 179, Issue 5, 2007, Pages 2681-2685

  Shibata, Wataru ^a,b   Maeda, Shin ^a,b   Hikiba, Yohko ^a   Yanai, Ayako ^a   Ohmae, Tomoya ^b   Sakamoto, Kei ^b   Nakagawa, Hayato ^b   Ogura, Keiji ^b   Omata, Masao ^b  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; I KAPPA B KINASE GAMMA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEMO BINDING DOMAIN PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DEXTRAN SULFATE; I KAPPA B KINASE; LIPOPOLYSACCHARIDE; NBD PEPTIDE, MOUSE; PEPTIDE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; COLITIS; COLON INJURY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENTERITIS; ENZYME BINDING; ENZYME INHIBITION; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; I-KAPPA B KINASE; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NF-KAPPA B; PEPTIDES; TRINITROBENZENESULFONIC ACID;

EID: 38449110152     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.5.2681     Document Type: Article

References (20)

1. Girardin, S. E., J. P. Hugot, and P. J. Sansonetti. 2003. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 24: 652-658.
2. Fiocchi, C. 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182-205.
3. Podolsky, D. K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417-429.
4. Wahl, C., S. Liptay, G. Adler, and R. M. Schmid. 1998. Sulfasalazine: a potent and specific inhibitor of NF-κB. J. Clin. Invest. 101: 1163-1174.
5. Ghosh, S. and M. Karin. 2002. Missing pieces in the NF-κB puzzle. Cell 109: S81-S96.
6. Karin, M., and A. Lin. 2002. NF-κB at the crossroads of life and death. Nat. Immunol. 3: 221-227.
7. Rothwarf, D. M. and M. Karin. 1999. The NF-κB activation pathway: A paradigm in information transfer from membrane to nucleus. Science's STKE 26: RE1.
8. Li, Z.-W., W. Chu, Y. Hu, M. Delhase, T. Deerinck, M. Ellisman, R. Johnson, and M. Karin. 1999. The IKKβ subunit of IκB kinase (IKK) is essential for NF-κB activation and prevention of apoptosis. J. Exp. Med. 189: 1839-1845.
9. Li, Q., D. Van Antwerp, F. Mercurio, K.-F. Lee, and I. M. Verma. 1999. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 284: 321-325.
10. Maeda, S., M. Akanuma, Y. Mitsuno, Y. Hirata, K. Ogura, H. Yoshida, Y. Shiratori, and M. Omata. 2001. Distinct mechanism of Helicobacter pylori-mediated NF-κB activation between gastric cancer cells and monocytic cells. J. Biol. Chem. 276: 44856-44864.
11. May, M. J., F. D'Acquisto, L. A. Madge, J. Glockner, J. S. Pober, and S. Ghosh. 2000. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex. Science 289: 1550-1554.
12. Cyrus, T., S. Sung, L. Zhao, C. D. Funk, S. Tang, and D. Pratico. 2002. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in lowdensity lipoprotein receptor-deficient mice. Circulation 106: 1282-1287.
13. Nathens, A. B., R. Bitar, C. Davreux, M. Bujard, J. C. Marshall, A. P. B. Dackiw, R. W. G. Watson, and O. D. Rotstein. 1997. Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury. Am. J. Respir. Cell Mol. Biol. 17: 608-616.
14. Dieleman, L. A., M. J. Palmen, H. Akol, E. Bloemena, A. S. Pena, S. G. Meuwissen, and E. P. Van Rees. 1998. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114: 385-391.
15. Fichtner-Feigl, S., I. J. Fuss, J. C. Preiss, W. Strober, and A. Kitani. 2005. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-κB decoy oligonucleotides. J. Clin. Invest. 115: 3057-3071.
16. De Vry, C. G., S. Prasad, L. Komuves, C. Lorenzana, C. Parham, T. Le, S. Adda, J. Hoffman, N. Kahoud, R. Garlapati, et al. 2007. Non-viral delivery of nuclear factor-κB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 56: 524-533.
17. Karin, M., Y. Yamamoto, and Q. M. Wang. 2004. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discovery 3: 17-26.
18. Beg, A. A., W. C. Sha, R. T. Bronson, S. Ghosh, and D. Baltimore. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376: 167-170.
19. Greten, F. R., L. Eckmann, T. F. Greten, J. M. Park, Z.-W. Li, L. J. Egan, M. F. Kagnoff, and M. Karin. 2004. IKKβ links inflammation and tumorigenesis in a mouse model of colitis associated cancer. Cell 118: 285-296.
20. O'Neil, D. A., E. M. Porter, D. Elewaut, G. M. Anderson, L. Eckmann, T. Ganz, and M. F. Kagnoff. 1999. Expression and regulation of the human β-defensins hBD-1 and hBD-2 in intestinal epithelium. J. Immunol. 163: 6718-6724.